Kansai International Airport’s Populous Redesigned Terminal 1 Opens Ahead of World Expo 2025
Kansai Airports and global design firm Populous have been working for more than seven years to completely reimagine the airport’s floor plan, bringing a new level of efficiency and experience for travellers to Japan’s west.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250331282189/en/
KANSAI INTERNATIONAL AIRPORT'S POPULOUS REDESIGNED TERMINAL 1 OPENS AHEAD OF WORLD EXPO 2025. The final phase of the refurbished Kansai International Airport (KIX) Terminal 1 has opened on 27 March 2025 to accommodate the millions of passengers expected to pass through the iconic building to attend World Expo in Osaka. Kansai Airports and global design firm Populous have been working for more than seven years to completely reimagine the airport's floor plan, bringing a new level of efficiency and experience for travellers to Japan's west.
Populous Senior Principal and Director, Brett Wightman, said the original Kansai International Airport (KIX) Terminal 1 wanted to make the best possible use of the existing infrastructure and maximize commercial return for Kansai Airports.
“Working closely with the facility operators, key stakeholders and end users, as well as expert retail and planning consultants, we have been able to craft a design that is built upon operational functionality, passenger convenience, accessibility and sustainability, while delivering innovative solutions that create an authentic and experiential environment with a clearly defined spirit of place,” Mr Wightman said.
The new Terminal 1 includes a 60% increase in the size of the international departure lounge and retail offerings, the introduction of innovative retail layouts based on passenger experiences, and the creation of a seamless processing experience.
PHASED RENOVATION TO ALLOW FOR CONTINUED OPERATIONS
Populous led the architecture and interior design of the redevelopment, as well overseeing the project throughout construction.
Mr Wightman said, importantly, the design considered operational functionality during renovation.
The project has been completed in four phases to allow for continued operations of the airport, which is expected to accommodate more than 40 million passengers a year from 2025 and almost double international capacity.
In October 2022, KIX opened the new Phase 1 domestic area followed by the new international area. Phase 2 of the project was completed in December 2023, and included 6,650 square meters of additional airside retail outlets, 1,130 square meters of food and beverage space and a new centralized immigration area.
The Populous team and Kansai Airports completed Phase 3 on March 27, 2025, allowing the consolidation and extension of the security screening area to be ready before World Expo 2025 begins in April in Osaka.
PHASE 3 – INTERNATIONAL SECURITY CHECKPOINT OPENS 27 MARCH 2025
Phase 3 includes faster, more comfortable and smoother security inspection with additional smart lanes capable of processing between 4,500 and 6,000 passengers an hour.
The new queuing management system is the first of its kind in Japan, automatically controlling flapper gates to switch waiting lines by utilizing real-time passenger flow data. The system enables passengers to be automatically guided to the security inspection lanes based on the number of passengers and their flow.
A new commercial area includes 13 stores across international departures, international arrivals and a street food court.
The project has already been recognised for its architectural vision as a finalist in the 2023 World Architecture Festival Awards for Future Projects – Infrastructure.
Originally designed by world renowned Italian architect Renzo Piano, the airport is considered an architectural icon. Regarded as part of the high-tech architecture movement of the 1990s, KIX’s industrial design is famous for its asymmetrical clear-span sweeping aerofoil roofline. At 1.7km long, it is one of the longest airport passenger terminal buildings in the world.
Principal Design Manager, Architect Jack Kato said the redesign had to respect the old while embracing new commercial opportunities for passengers.
“We broke away from the former gray color scheme, reinvigorating the interior spaces with a palette of natural materials to give the terminal a distinctly Japanese feel, but at the same time we opened up areas like the relocated immigration hall to provide an open space reflecting the original architecture and offering an inspiring arrival experience to start each journey,” Mr Kato said.
“This will transform the arrival experience of each journey into something inspirational.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331282189/en/
Contacts
Charlie Brooks
Charlie.brooks@populous.com
+44 7881268501
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom